Webinar

Virtual Event

BIO Digital Health Track at BIO Digital: Virtual BIO International Convention

June 8 – 11, 2020
Event details
June 8 – 11, 2020
12:00 – 12:00 am Pacific Standard Time

Event summary

Cooley chairs Digital Health Track at BIO Digital, the 2020 Virtual BIO International Convention.

Cooley’s leadership in digital health is no accident. We are proud to support BIO Digital, providing access to key partners via BIO one-on-one partnering, educational resources to help drive business, and insights needed to continue critical research and development.

Cooley partner Wainwright Fishburn serves as chair of the Digital Health Track. Cooley Partners Josh Seidenfeld and Erin Estevez are featured speakers.

Featured agenda items

June 9, 2020, 3:30 pm – 4:25 pm PDT
Investors Corner: Digital Health Funding Outlook – Raising Money During Economic Uncertainty

Investors discuss the 2020 digital health funding outlook, the pandemic’s effect on the sector, what criteria investors are seeking to lead a deal and which sub-sectors are poised for unprecedented success.

Speakers
Ruoxi Chen – Principal, Warburg Pincus
Wainwright Fishburn – Partner and Global Head, Digital Health, Cooley
Thomas Kluz – Senior Investment Manager, Qualcomm Ventures
Jessica Zeaske – Partner, Echo Health Ventures


June 11, 2020, 3:30 pm – 4:25 pm PDT
Federal Economic Recovery Efforts for Small Biotechnology Companies

From paid sick leave for employees to the controversial Paycheck Protection Program to future legislative proposals, the Federal government is rolling out substantial assistance for small businesses. Come learn about whether and how these programs will benefit small biotechs and BIO’s priority economic proposals for future legislation.

Speakers
Cameron Arterton – Vice President of Tax Policy and Emerging Companies, Biotechnology Innovation Organization (BIO)
Marc Belsky – Chief Financial Officer and Secretary, Kezar Life Sciences
Erin Estevez – Special Counsel, Cooley
Justin Field – SVP of Government Affairs, NVCA


On demand
Digitizing the genome: Enabling new models for population – scale genomics
Learn how health systems, life sciences companies and payers are working together to address obstacles and use “digitized” genomics to accelerate drug discovery, development, commercialization and to improve outcomes for patients.

Speakers
Joe Grzymski – CSO, Renown Health
Katrina Loomis – Executive Director and Head of Emerging Portfolio: Emerging Science & Innovation, Pfizer
James Lu – Co-founder and CSO, Helix
Josh Seidenfeld – Partner, Cooley


On demand
Asymmetrical Challenges of Innovation

Leading executives will share insights, discuss the challenges they faced in becoming an established player and will offer perspectives for new innovators in the ecosystem.

Speakers
Jeff Margolis – Chairman of the Board, Welltok
Corey McCann – Founder & CEO, Pear Therapeutics
Rebecca Robbins – San Francisco Correspondent, STAT News
 
Glen Tullman – Executive Chairman and Founder, Livongo Health


Event details and registration 

For more information, please email Ilana Brand.

 

 

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.